United States securities and exchange commission logo

                             August 26, 2020

       Eli Casdin
       Chief Executive Officer
       CM Life Sciences, Inc.
       c/o Corvex Management LP
       667 Madison Avenue
       New York, NY 10065

                                                        Re: CM Life Sciences,
                                                            Amendment No. 1 to
Registration Statement on Form S-1
                                                            Filed August 24,
                                                            File No. 333-246251

       Dear Mr. Casdin:

             We have reviewed your amended registration statement and have the
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Amendment No. 1 to Registration Statement on Form S-1


   1.                                                   We note your risk
factor disclosure on page 56 discloses that your warrant agreement has
                                                        an exclusive forum
clause which shall be applicable to any action, proceeding or claim
                                                        against you arising out
of or relating in any way to the warrant agreement, including under
                                                        the Securities Act, but
that such provision will not apply to suits brought to enforce any
                                                        liability or duty
created by the Exchange Act. Please also ensure that the forum selection
                                                        provision in Section
9.3 of your Form of Warrant Agreement filed as Exhibit 4.4 states
                                                        this clearly, or tell
us how you will inform investors in future filings that the provision
                                                        applies to actions
arising under the Securities Act, but not the Exchange Act.
 Eli Casdin
CM Life Sciences, Inc.
August 26, 2020
Page 2

       You may contact Jennifer O'Brien, Staff Accountant, at (202) 551-3721 or
Horowitz, Accounting Branch Chief, at (202) 551-3311 if you have questions
comments on the financial statements and related matters. Please contact Karina
Dorin, Staff
Attorney, at (202) 551-3763 or Kevin Dougherty, Staff Attorney, at (202)
551-3271 with any
other questions.

FirstName LastNameEli Casdin
                                                           Division of
Corporation Finance
Comapany NameCM Life Sciences, Inc.
                                                           Office of Energy &
August 26, 2020 Page 2
cc:       Colin Diamond
FirstName LastName